Company intelligence
Menten AI
Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Generative AI.
Biotechnology Research
San Francisco, US
19 employees
Founded 2020
1 public signals
About Menten AI
Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability. We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.
Verified activity
Signals from Menten AI
1 published signal